The National Agency for Food and Drug Administration and Control (NAFDAC) has ordered the recall of Acetazolamide Tablets USP 125mg from the market.
The affected product, manufactured by the American pharmaceutical company Rubicon Research Private Ltd., is identified by batch number 30575HF1.
The recall was prompted after the discovery of a contaminated batch, which included tablets that were discolored and found to be dirty.
NAFDAC said in a statement on Tuesday, November 26 that, “Acetazolamide is a potent carbonic anhydrase inhibitor, effective in the control of fluid secretion (e.g., some types of glaucoma), in the treatment of certain convulsive disorders (e.g., epilepsy), and in the promotion of diuresis in instances of abnormal fluid retention (e.g., cardiac edema).
“Acetazolamide is a diuretic used in the treatment of swelling caused by heart disease. It also works by helping the body generate more urine to lose salt and excess water from the body. It can also treat seizures, certain types of glaucoma, and prevent symptoms of altitude sickness.”
NAFDAC has urged importers, distributors, retailers, and consumers to remain vigilant and cautious throughout the supply chain to prevent the importation, distribution, sale, and use of the affected product batches.
The agency also emphasized that medical products should only be sourced from authorized and licensed suppliers, and that the authenticity and condition of the products should be thoroughly verified before use.
“Anyone in possession of the affected lots is advised to immediately discontinue sale or use and submit stock to the nearest NAFDAC office,” it noted.
“If you have used this product, or someone you know has used it, or suffered any adverse reaction/event after use, you are advised to seek immediate medical advice from a qualified healthcare professional.”
Comments